Septerna (SEPN) Competitors

Amneal Pharmaceuticals has a net margin of 4.01% compared to Septerna's net margin of -49.88%. Septerna's return on equity of -12.72% beat Amneal Pharmaceuticals' return on equity.

In the previous week, Septerna had 10 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 16 mentions for Septerna and 6 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.74 beat Septerna's score of -0.06 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media.

Amneal Pharmaceuticals has higher revenue and earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Comparatively, 4.3% of Septerna shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Amneal Pharmaceuticals has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market. Comparatively, Septerna has a beta of 2.21, suggesting that its stock price is 121% more volatile than the broader market.

Amneal Pharmaceuticals currently has a consensus price target of $15.00, indicating a potential upside of 25.84%. Septerna has a consensus price target of $43.13, indicating a potential upside of 63.97%. Given Septerna's higher probable upside, analysts plainly believe Septerna is more favorable than Amneal Pharmaceuticals.

Septerna has higher revenue and earnings than Crinetics Pharmaceuticals. Septerna is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Crinetics Pharmaceuticals has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market. Comparatively, Septerna has a beta of 2.21, meaning that its stock price is 121% more volatile than the broader market.

Crinetics Pharmaceuticals presently has a consensus target price of $76.13, suggesting a potential upside of 119.38%. Septerna has a consensus target price of $43.13, suggesting a potential upside of 63.97%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Crinetics Pharmaceuticals is more favorable than Septerna.

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are held by company insiders. Comparatively, 4.3% of Septerna shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Septerna had 8 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 16 mentions for Septerna and 8 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 0.09 beat Septerna's score of -0.06 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media.

Septerna has a net margin of -49.88% compared to Crinetics Pharmaceuticals' net margin of -2,747.18%. Septerna's return on equity of -12.72% beat Crinetics Pharmaceuticals' return on equity.

Septerna presently has a consensus target price of $43.13, suggesting a potential upside of 63.97%. MANE has a consensus target price of $100.00, suggesting a potential downside of 0.88%. Given Septerna's higher possible upside, research analysts plainly believe Septerna is more favorable than MANE.

In the previous week, Septerna had 11 more articles in the media than MANE. MarketBeat recorded 16 mentions for Septerna and 5 mentions for MANE. Septerna's average media sentiment score of -0.06 beat MANE's score of -0.47 indicating that Septerna is being referred to more favorably in the media.

MANE has lower revenue, but higher earnings than Septerna.

MANE has a net margin of 0.00% compared to Septerna's net margin of -49.88%. MANE's return on equity of 0.00% beat Septerna's return on equity.

79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 4.3% of Septerna shares are held by company insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Septerna currently has a consensus price target of $43.13, suggesting a potential upside of 63.97%. Catalyst Pharmaceuticals has a consensus price target of $32.17, suggesting a potential upside of 3.00%. Given Septerna's higher probable upside, research analysts plainly believe Septerna is more favorable than Catalyst Pharmaceuticals.

Septerna has a beta of 2.21, suggesting that its share price is 121% more volatile than the broader market. Comparatively, Catalyst Pharmaceuticals has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market.

In the previous week, Septerna had 14 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 16 mentions for Septerna and 2 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 0.61 beat Septerna's score of -0.06 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media.

Catalyst Pharmaceuticals has higher revenue and earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Septerna's net margin of -49.88%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Septerna's return on equity.